CompletedPhase 4NCT04464434

Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
UMC Utrecht
Principal Investigator
Jacob M van Laar, MD PhD
UMC Utrecht
Intervention
Upfront autologous HSCT(procedure)
Enrollment
60 enrolled
Eligibility
18-65 years · All sexes
Timeline
2020 – 2026

Study locations (8)

Collaborators

ZonMw: The Netherlands Organisation for Health Research and Development · Boehringer Ingelheim · Miltenyi Biotec, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04464434 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis →

← Back to all trials